Alpha Radiation Emitters Device for the Treatment of Cutaneous Mucosal and Superficial Soft Tissue Neoplasia (DaRT)

  • STATUS
    Recruiting
  • End date
    Sep 27, 2022
  • participants needed
    35
  • sponsor
    Alpha Tau Medical LTD.
Updated on 27 July 2021
cancer
cancer treatment

Summary

A unique approach for cancer treatment employing intratumoral diffusing alpha radiation emitter device for superficial cutaneous, mucosal or soft tissue neoplasia

Description

This will be a prospective, open label, single arm, controlled study, assessing the safety and efficacy of diffusing alpha emitters radiation therapy (DaRT) delivered through radioactive seeds inserted into the tumor.

This approach combines the advantages of local intratumoral irradiation of the tumor, as used in conventional brachytherapy, with the power of the alpha radiation emitting atoms, that will be introduced in quantities considerably lower than radiation therapy already used in patients.

Superficial lesions with histopathological confirmation of malignancy will be treated using DaRT seeds.

Reduction in tumor volume and evaluation the percent of necrotic tissue in the tumor 30-45 days after DaRT seeds insertion (15-30 days after seed removal) will be assessed. Safety will be assessed by the cumulative incidence, worst severity and frequency of adverse events (AEs) observed including the follow-up period.

Details
Condition Soft tissue tumor, melanoma, skin cancer, Mucosal Neoplasm of Oral Cavity, soft tissue tumour, soft tissue tumors, skin cancers
Treatment Device: Radiation: Diffusing Alpha Radiation Emitters Therapy (DaRT)
Clinical Study IdentifierNCT03886181
SponsorAlpha Tau Medical LTD.
Last Modified on27 July 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Subjects with histopathological confirmation of cutaneous and/or mucosal and/or superficial soft tissue malignant neoplasia
Subjects with a tumor size 5 centimeters in the longest diameter
Subjects' age is over 18 years old
Subjects' ECOG Performance Status Scale is < 2\
Subjects' life expectancy is more than 6 months
Women of childbearing potential (WOCBP) will have evidence of negative pregnancy test
Subjects are able and willing to sign an informed consent form

Exclusion Criteria

Subject has a tumor with a maximal diameter > 5 centimeters
Subjects' ECOG Performance Status Scale is > 3\
Subject has a tumor of Keratoacanthoma histology
Patients with moribund diseases, e.g., autoimmune diseases, vasculitis, etc
Patients under systemic immunosuppressive and/or corticosteroid treatment. Patients taking corticosteroid inhalers are eligible
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note